In the last year of pandemic, several variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been identified and monitored. Indeed, the persisting challenges of SARS-CoV-2 to the international public health system elicit concerns on the effects of mutations among scientists, drug and vaccine developers [1]. In this context, laboratory, epidemiological, and computational investigations (including some from our group) have been performed to investigate the effects of mutations on the binding with angiotensin-converting-enzyme 2 (ACE2) receptors, resistance against antibodies, and pathogenicity of the virus [2–4].
